EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension

Jason Weatherald iD, Thomas R Fleming, Martin R Wilkins iD, Thomas M Cascino, Mitchell A Psotka, Roham Zamanian, Werner Seeger iD, Nazzareno Galiè, Mardi Gomberg-Maitland

European Respiratory Journal · 2024-10 · 64 (4) · 2401205

DOI: 10.1183/13993003.01205-2024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 29.08.2024. Verfasst von Jason Weatherald und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada weathera@ualberta.ca. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Endpoint Determination, Pulmonary Arterial Hypertension, Research Design. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials in pulmonary arterial hypertension (PAH) have led to the approval of several effective treatments that improve symptoms, exercise capacity and clinical outcomes. In phase 3 clinical trials, primary end-points must reflect how a patient “feels, functions or survives”. In a rare disease like PAH, with an ever-growing number of treatment options and numerous candidate therapies being studied, future clinical trials are now faced with challenges related to sample size requirements, efficiency and demonstration of incremental benefit on traditional end-points in patients receiving background therapy with multiple drugs. Novel clinical trial end-points, innovative trial designs and statistical approaches and new technologies may be potential solutions to tackle the challenges facing future PAH trials, but these must be acceptable to patients and regulatory bodies while preserving methodological rigour. In this World Symposium on Pulmonary Hypertension task force article, we address emerging trial end-points and designs, biomarkers and surrogate end-point validation, the concept of disease modification, challenges and opportunities to address diversity and representativeness, and the use of new technologies such as artificial intelligence in PAH clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicEndpoint DeterminationPulmonary Arterial HypertensionResearch DesignHumansAntihypertensive AgentsArtificial IntelligenceBiomarkersTreatment Outcome

Substanzen

Antihypertensive AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada weathera@ualberta.ca.
  • Department of Biostatistics, University of Washington, Seattle, WA, USA.
  • National Heart and Lung Institute, Imperial College London, London, UK.
  • Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Inova Schar Heart and Vascular, Falls Church, VA, USA.
  • United States Food and Drug Administration, Silver Spring, MD, USA.

ORCID-Profile: Jason Weatherald, Martin R Wilkins, Werner Seeger

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Weatherald, J., Fleming, T. R., Wilkins, M. R., Cascino, T. M., Psotka, M. A., Zamanian, R., Seeger, W., Galiè, N., & Gomberg-Maitland, M. (2024). Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension. European Respiratory Journal, 64(4), 2401205. https://doi.org/10.1183/13993003.01205-2024

Vancouver

Weatherald J, Fleming TR, Wilkins MR, Cascino TM, Psotka MA, Zamanian R, et al. Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension. European Respiratory Journal. 2024;64(4):2401205. doi:10.1183/13993003.01205-2024

BibTeX
@article{Weatherald2024,
  author = {Weatherald, Jason and Fleming, Thomas R and Wilkins, Martin R and Cascino, Thomas M and Psotka, Mitchell A and Zamanian, Roham and Seeger, Werner and Galiè, Nazzareno and Gomberg-Maitland, Mardi},
  title = {Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {64},
  number = {4},
  pages = {2401205},
  doi = {10.1183/13993003.01205-2024}
}
Kostenlos starten →